Linden Capital completed the acquisition of a majority stake in BioIVT from Arsenal Capital.

Linden Capital, a healthcare private equity firm, completed the acquisition of a majority stake in BioIVT, a provider of mission-critical biological specimens and value-added services, from Arsenal Capital, a private equity firm. Financial terms were not disclosed. "We are delighted to have worked with the talented management team and employees of BioIVT in executing an ambitious growth strategy to build a market-leading company. BioIVT is uniquely positioned to facilitate the safe and effective progress of research to bring therapeutics and diagnostics to all of us whose health and wellbeing are supported by advances in science and clinical care," Dave Spaight, Arsenal Operating Partner.